<unk> , sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.<unk>  is an interleukin 1 inhibitor.<unk>  is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.<unk>  was given an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome.<unk>  is the first drug approved by the FDA to treat recurrent pericarditis.<unk>  was approved for medical use in the United States in February 2008. On May 8, 2012 an FDA Advisory Panel voted 11–0 against the approval of<unk>  for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.
Rilonacept
Rivastigmine
Glysobuzole
Glybuzole
Nusinersen
Memantine
Carbidopa/levodopa
Belinostat